BLINCYTO vs GLEEVEC

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. BLINCYTO and GLEEVEC are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BLINCYTO	GLEEVEC
Rating	72/100	70/100
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	BLINATUMOMAB	IMATINIB MESYLATE
Manufacturer	Amgen Inc	Novartis
Dosage forms	Kit	Tablet
Drug class	—	Kinase Inhibitor
Boxed warning	Boxed warning	None
Treats	Lymphoid Leukemia	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

blincyto gleevec

Rating

72/100

70/100

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

BLINATUMOMAB

IMATINIB MESYLATE

Manufacturer

Amgen Inc

Novartis

Dosage forms

Kit

Tablet

Drug class

—

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

Which is better-rated, Blincyto or Gleevec?

By our independent rating, Blincyto scores higher — 3.6 vs 3.5 out of 5 for Gleevec. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Blincyto and Gleevec?

Blincyto contains Blinatumomab, while Gleevec contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.